Today Achaogen Inc (NASDAQ:AKAO) Reported Decrease in Shorted Shares

Achaogen, Inc. (NASDAQ:AKAO) Logo

Investors sentiment increased to 0.93 in 2018 Q3. Its up 0.24, from 0.69 in 2018Q2. It is positive, as 19 investors sold Achaogen, Inc. shares while 21 reduced holdings. 17 funds opened positions while 20 raised stakes. 17.23 million shares or 23.75% less from 22.60 million shares in 2018Q2 were reported.
Virtu Fincl Ltd Liability Corp has invested 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO). Point72 Asset Mgmt Lp accumulated 0% or 100,000 shares. Moreover, Millennium Mgmt Limited Liability Corp has 0% invested in Achaogen, Inc. (NASDAQ:AKAO). Schwab Charles Investment Management, a California-based fund reported 147,306 shares. Architects has invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Alliancebernstein L P owns 60,700 shares. Vanguard Group reported 1.68 million shares or 0% of all its holdings. Deutsche Comml Bank Ag holds 0% or 201,763 shares. Northern Tru invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Rhumbline Advisers, Massachusetts-based fund reported 28,885 shares. The Maryland-based Price T Rowe Associate Md has invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Meeder Asset Management owns 417 shares. Citigroup stated it has 17,008 shares or 0% of all its holdings. 2,546 were accumulated by Ameritas Prns Inc. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 1,712 shares.

Since June 26, 2018, it had 3 insider purchases, and 7 selling transactions for $689,450 activity. Another trade for 157,760 shares valued at $281,606 was bought by DUGGAN ROBERT W. Hillan Kenneth J. sold $7,135 worth of stock or 744 shares. Schilke Tobin sold $2,858 worth of Achaogen, Inc. (NASDAQ:AKAO) on Tuesday, June 26. 450 Achaogen, Inc. (NASDAQ:AKAO) shares with value of $4,316 were sold by Dorling Janet. The insider LOEB GARY sold $4,308.

The stock of Achaogen Inc (NASDAQ:AKAO) registered a decrease of 0.77% in short interest. AKAO’s total short interest was 8.04M shares in December as published by FINRA. Its down 0.77% from 8.10 million shares, reported previously. With 1.16 million shares average volume, it will take short sellers 7 days to cover their AKAO’s short positions. The short interest to Achaogen Inc’s float is 28.36%.

The stock increased 2.98% or $0.05 during the last trading session, reaching $1.73. About 1.74M shares traded or 103.29% up from the average. Achaogen, Inc. (NASDAQ:AKAO) has declined 83.95% since December 11, 2017 and is downtrending. It has underperformed by 83.95% the S&P500.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $79.79 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Coverage

Among 8 analysts covering Achaogen (NASDAQ:AKAO), 0 have Buy rating, 1 Sell and 7 Hold. Therefore 0 are positive. Achaogen had 12 analyst reports since June 26, 2018 according to SRatingsIntel. H.C. Wainwright downgraded the shares of AKAO in report on Monday, November 12 to “Neutral” rating. The stock of Achaogen, Inc. (NASDAQ:AKAO) has “Hold” rating given on Friday, November 9 by Stifel Nicolaus. The firm earned “Market Perform” rating on Friday, November 9 by Cowen & Co. On Tuesday, November 13 the stock rating was downgraded by SunTrust to “Hold”. The firm has “Neutral” rating by Mizuho given on Friday, November 9. The rating was maintained by Needham on Tuesday, June 26 with “Buy”. The stock of Achaogen, Inc. (NASDAQ:AKAO) has “Buy” rating given on Tuesday, August 7 by Stifel Nicolaus. As per Tuesday, August 7, the company rating was downgraded by Needham. Mizuho maintained Achaogen, Inc. (NASDAQ:AKAO) on Wednesday, June 27 with “Buy” rating. The firm has “Neutral” rating given on Monday, November 12 by Wedbush.

More notable recent Achaogen, Inc. (NASDAQ:AKAO) news were published by: Seekingalpha.com which released: “Achaogen After Ad Comm – Seeking Alpha” on May 07, 2018, also Benzinga.com with their article: “31 Stocks Moving In Monday’s Pre-Market Session – Benzinga” published on December 10, 2018, Seekingalpha.com published: “JPMorgan downgrades Infinity Pharma to Underweight in premarket analyst action – Seeking Alpha” on November 12, 2018. More interesting news about Achaogen, Inc. (NASDAQ:AKAO) were released by: Nasdaq.com and their article: “Achaogen Announces FDA Clearance and Launch of the Thermo Scientific QMS Plazomicin Immunoassay – Nasdaq” published on December 10, 2018 as well as Seekingalpha.com‘s news article titled: “Achaogen: Falling Knife Or Major Bargain? – Seeking Alpha” with publication date: June 28, 2018.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.